Addex spin-out Neurosterix completes Phase 1 trials of NTX-253 in schizophrenia, targets Phase 2

• Addex reported its spin-out Neurosterix completed Phase 1 studies of NTX-253 for schizophrenia.
• Results have already been generated; no future presentation was specified.
• Data supported a decision to advance NTX-253 into Phase 2 development.
• NTX-253 is an M4 receptor positive allosteric modulator aimed at treating schizophrenia.
• Addex holds a 20% equity stake in Neurosterix, which raised $65 million in Series A financing in April 2024.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Addex Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610080100OMX_____CNEWS_EN_GNW1001276833_en) on October 08, 2026, and is solely responsible for the information contained therein.